SEC Form 4 · accession 0001209191-16-141765

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 14, 2016

Accepted (ET)

Sep 16, 2016 · 3:21 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Sep 14, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Sep 14, 2016	S	400	$88.76	D	274,325	D
Common Stock^F2,F4	Sep 14, 2016	S	3,500	$89.80	D	270,825	D
Common Stock^F2,F5	Sep 14, 2016	S	200	$90.27	D	270,625	D
Common Stock^F2,F6	Sep 14, 2016	S	700	$96.20	D	269,925	D
Common Stock^F2,F7	Sep 14, 2016	S	1,700	$97.17	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$36.30	Sep 14, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	112,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $88.76 (range $88.22 to $88.99).
F4Open market sales reported on this line occurred at a weighted average price of $89.80 (range $89.26 to $90.20).
F5Open market sales reported on this line occurred at a weighted average price of $90.27 (range $90.26 to $90.28).
F6Open market sales reported on this line occurred at a weighted average price of $96.20 (range $95.78 to $96.72).
F7Open market sales reported on this line occurred at a weighted average price of $97.17 (range $96.83 to $97.71).
F8Fully vested.